Background: Acute kidney injury (AKI) accounts for up to 60% of hospitalized patients in intensive care units and is a widespread diagnosis. Recent years have seen an increase in risk factors for it, including old age, chronic diabetes, and kidney disease (CKD). The definition of acute kidney injury (AKI), formerly known as acute renal failure, is a rapid decrease in the glomerular filtration rate. Nephrotoxicity is mainly caused by drugs and auto-immune-induced kidney injury, which is defined by immune cell infiltration in the tubulointerstitial. Interleukin-1B (IL-1B) and tumor necrosis factor-alpha (TNF-α) are signs of kidney inflammation. Objective: Evaluate the Anti-inflammatory effect of ertugliflozin. Materials & Methods: Thirty adult male albino rats were recruited. These rats were raised in an animal house with a special commercial diet and water. After ten days of acclimatization, the selected rats were separated at random into three groups. Each experimental group consisted of ten rats. This study ran from December 18, 2023, to January 1, 2024, and was carried out in the Animal House of the College of Medicine/University of Babylon. Serum samples were taken for measuring IL-1B and TNF-α. Result: The results demonstrated that ertugliflozin provides anti-inflammatory in the treated groups. The two parameters manifest it. Conclusion: The results emphasize that ertugliflozin has an anti-inflammatory effect.